TrialThrombosis and haemostasis2025

A Phase 1b PK/PD Study to Demonstrate Antigen Elimination with RLYB212, A Monoclonal Anti-HPA-1a Antibody for FNAIT Prevention.

Christof Geisen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.